Acetaminophen (APAP)-induced liver injury is initiated by metabolism of APAP by the cytochrome P-450 (CYP) system, primarily CYP2E1. We previously demonstrated CYP inhibition following administration of a liquid APAP formulation containing propylene glycol, a CYP2E1 inhibitor, and other excipients.This study was undertaken to determine if propylene glycol specifically inhibits production of CYP-derived metabolites and if propylene glycol reduces the rise in alanine aminotransferase (ALT) seen following prolonged APAP dosing. Human subjects were randomized to receive 4 g of APAP daily in one arm of the study or 4 g of APAP with 5 mL of 99% propylene glycol in the other arm, both for 14 days. After a washout period of at least 14 days, subjects were crossed over between arms. Outcomes were rise of ALT greater than 2 times baseline (responders) and proportion of randomly sampled CYP-derived metabolites relative to total metabolites produced. There was no difference in percentage of responders between treatment groups: 6 of 21 in the APAP group (29%) compared with 8 of 20 in the APAP + propylene glycol group (40%); chi-square, P = .59. For all subjects, the mean percentage of CYP-derived metabolites produced was 5.8% (APAP) versus 4.3% (APAP + propylene glycol); P = .018. This effect was solely attributable to the responders: the mean percentage of CYP metabolites of responders was 7.7% (APAP) versus 4.6% (APAP + propylene glycol), P = .050, whereas there was no difference for the nonresponders. Five subjects were responders in both arms (2% probability of random occurrence). Our data indicates that propylene glycol inhibits CYP2E1 metabolism of APAP in some subjects but does not effect hepatocellular indury at the dose given.
The majority of ingested APAP is conjugated with glucuronide and sulfate, whereas approximately 5%-15% of a dose is metabolized via the cytochrome P-450 (CYP) system, primarily via CYP2E1, with contribution from CYP1A2, CYP3A4, and CYP2A6 [7] [8] [9] [10] ( Figure 1 ). This reductive metabolism via the CYP system results in the production of a radical metabolite, n-acetyl-p-benzoquinone imine (NAPQI). 11 NAPQI binds intracellular glutathione, thus forming the CYP metabolites APAP-glutathione, APAP-cysteinate, and APAPmercapturate. Most investigators and clinicians believe that the hepatocellular damage is initiated by NAPQI arylating intracellular proteins once glutathione stores are depleted. 12, 13 Data obtained from studies in rodents and in vitro reveal that CYP2E1 activity is primarily responsible for the development of hepatotoxicity. 14 We previously reported that after taking an equivalent 15 mg/kg APAP dose in a solid versus liquid preparation, healthy adult volunteers produced significantly less CYP metabolites following ingestion of the liquid preparation. 15 We theorized that this effect was because of the presence of propylene glycol, a common excipient found in the liquid preparation, although other Figure 1 . Metabolism of APAP. P450 metabolism results in NAPQI radical production, which binds and reduces levels of intracellular glutathione, leading to decreased redox buffering capacity. NAPQI arylated proteins and initiates toxicity. APAP CYP metabolites include APAP glutathione, APAP cysteinate, and APAP mercapturate.
excipients were present and may have contributed to the effects seen. In murine and in vitro models of APAP toxicity, propylene glycol reduced hepatocellular injury via inhibition of CYP2E1. 16, 17 Further, children are less susceptible to APAP toxicity. 18 We have speculated that this may be because of excipients, which inhibit CYP metabolism in the liquid pediatric preparations they are more likely to ingest.
The objective of this study was to determine if administration of propylene glycol in amounts that could be clinically feasible could have a protective effect on APAP-induced hepatocellular injury in human volunteers, as measured by subclinical ALT elevation similar to that seen in previous studies of 4-g APAP daily dosing. A secondary objective was to determine if administration of propylene glycol alone in addition to APAP would decrease CYP metabolite formation, presumably by inhibition of CYP2E1.
Methods

Study Protocol
This study was approved by the Institutional Committee on Clinical Investigation at the Beth Israel Deaconess Medical Center, the institutional review board. All subjects signed a written informed consent on entry into the study. We employed a crossover study design with 2 separate study arms. Subjects were randomized to start with either APAP alone or APAP and propylene glycol. APAP was orally dosed at 1 g 4 times per day for 14 days. In the APAP + propylene glycol arm, the subjects concurrently took 5 mL of 99% pharmaceutical-grade propylene glycol dissolved in 5 ounces of water with the APAP dose. Dosing of APAP was identical in both arms. Subjects were instructed to take the study medications 4 times per day at home at standard intervals. Subjects were seen in our institution's Clinical Research Center (CRC) daily for blood draws and to be interviewed by a nurse regarding any adverse effects or issues with compliance with the protocol. Compliance with dosing was confirmed by a research nurse during daily visits, and acetaminophen concentration was checked daily.
Our institutional review board believed there was minimal risk to subjects, given multiple previous studies of acetaminophen dosing of healthy adults at the maximum daily recommended dose of 4 g showing transient serum aminotransferase elevation without development of liver dysfunction and resolution even with continued administration. [4] [5] [6] propylene glycol is generally regarded as safe and is a common oral, topical, and parenteral pharmaceutical excipient. High intravenous doses have been implicated in acute and chronic toxicity. 19 In cases of toxicity in which propylene glycol plasma concentrations were reported, these far exceeded the concentrations we would expect, given our dosing regimen. 15, 19 Large oral doses appear to be well tolerated. Patients taking amprenavir in the standard dose of 1400 mg twice daily have a propylene glycol intake of more than 20 mL per day. We know of no reported adverse events attributable to propylene glycol associated with amprenavir. Propylene glycol is not a known carcinogen or teratogen.
Blood draws were not timed specifically to coincide with study medication dosing and so were considered random time samples. AST and ALT were measured immediately after the daily blood draw and reviewed to ensure that subjects were not developing liver injury requiring intervention. Subjects were allowed to continue taking APAP as long as AST or ALT did not reach 3 times the upper limit of normal. Subjects could be stopped at the discretion of the study physician as well. A second blood sample was centrifuged, and plasma was stored at -80°C for subsequent measurement of APAP metabolites. The subjects underwent a washout period of at least 14 days between the 2 arms of the study. This washout duration was deemed adequate based on the elimination half-life of acetaminophen and all its metabolites being less than 12 hours and ensured normal liver function tests on entry into each arm.
Subject Enrollment
Study subjects were identified by flyer and print advertising. Inclusion criteria were as follows: subjects were between 20 and 40 years of age, had no current prescription or over-the-counter medication use, were not pregnant, and had no prior significant medical history, specifically no history of liver disease or renal disease. Alcohol use was limited to 2 or fewer drinks no more than 4 times per week. Subjects responding to the advertisements were interviewed by a research assistant to determine if they met eligibility criteria. Eligible subjects were interviewed and examined by a study physician. Baseline complete blood counts, serum chemistries, ALT, AST, and urine pregnancy tests were obtained. A study physician subsequently reviewed the laboratory results, and subjects with no abnormalities on screening laboratory testing concerning examination findings or other contraindications were eligible to initiate the study.
Sample Analysis
Screening laboratory studies were performed at a commercial laboratory contracted with the CRC. Daily ALT and AST were measured in our Clinical Laboratory Improvement Amendments-certified hospital clinical laboratory.
APAP metabolites (APAP-glutathione, APAPmercapturate, APAP-cysteinate, APAP-sulfate, and APAP-glucuronide) were measured by high-performance liquid chromatography and tandem mass spectrometry (MS/MS) on a Shimadzu UFLC with autosampler and API 5000 triple quadrupole mass spectrometer (Sciex, Framingham, Massachusetts). Assay calibrators and isotopic standards were purchased from Toronto Research Chemicals Inc. (Toronto, Ontario, Canada).
Collected samples were immediately centrifuged, and plasma was aliquoted and stored at -80°C until thawed and extracted for analysis. Samples were thawed, extracted, and analyzed as a single batch. Storage time was 4-14 months. Stability of APAP and the reported metabolites under similar conditions for days to months has been previously reported. [20] [21] [22] In addition, the stability of metabolites during storage was validated by thawing and reanalyzing 10 of the samples 33 months after their original analysis. Repeat analysis confirmed that all metabolites recovered within ±20% of their original values. Twenty microliters of patient sample was mixed with 20 μL of isotopic standards (10 μg/mL of each standard), then precipitated with 160 μL of acetonitrile, spun, and supernatant transferred for analysis. Three microliters of extracted sample was injected for analysis; analytes were resolved by high-performance liquid chromatography on a polyhydroxyethyl A hydrophilic interaction chromatography column (100 × 2.1 mm, 3 μm bead diameter; purchased from PolyLC, Inc., Columbia, Maryland) using a gradient of acetonitrile/water containing 20 mM ammonium formate; analytes of interest were monitored by MS/MS multiple reaction monitoring. Acquisition was in positive ion mode, settings CAD 6, CUR 15, GS1 40, GS2 40, IS +2500V, collision energy 25, and source temperature 450˚C. For APAP and metabolites, the lower limit of quantification (LLOQ) was 0.24 μg/mL, and the upper limit of quantification was 12.5 μg/mL. All analytes had a coefficient of variation < 20% at the LLOQ.
Data Analysis
The primary outcome was the difference in percentage of "responders" between the 2 arms. Responders were defined as subjects who developed a peak ALT greater than 2 times the baseline. Baseline ALT was determined to be the mean of the ALT concentrations on the first 3 days of each study arm. Secondary outcomes included percentage of CYP-derived metabolite concentrations compared with all metabolites and AST and ALT mean and peak concentrations. APAP metabolite concentrations were measured at random intervals. Percentage of CYP metabolite concentrations were calculated as APAP-mercapturate + APAP-cysteinate concentrations divided by the sum of concentrations of all measured metabolites. We did not detect any measurable APAP-glutathione in the samples, so this was not included. As the samples were collected at random times compared with study medication dosing, we could not calculate area under the curve or total metabolite production. We therefore analyzed the percentage of CYP metabolites produced as opposed to attempting to interpret absolute metabolite concentrations or using metabolic ratios. This metabolite percentage approach at 2 and 4 hours after dosing correlated well with the calculated reduction in metabolite formation determined from the measured area under the curve when applied to the data from our previous acetaminophen metabolite study. 15 Categorical variables (ie, responders in each arm) were compared using the chi-square test. Paired continuous variables (ie, metabolite percentages for all subjects) with normal distribution of means were compared using the paired Student t test. Nonpaired continuous variables (ie, metabolite percentages for sets of subjects) were compared with the unpaired Student t test. The goal was to enroll 30 study subjects to detect 35% versus 5% discordant pairs with 80% power and 5% level of significance in the context of the McNemar test.
Results
Twenty-one subjects completed the protocol. Thirteen of the subjects were female (61%). The mean age of subjects was 29 years (range, 21-37 years). Eleven subjects were randomized to start in the APAP + propylene glycol group first. (Figure 2) . Data from the APAPpropylene glycol arm from 1 subject was not used, as we were unable to detect APAP metabolites in the samples collected during the APAP + propylene glycol arm. Dosing compliance was confirmed with daily acetaminophen concentrations: the mean acetaminophen concentration in all subjects was 10.2 μg/mL (range, Figure 3 . Responders (subjects who developed a peak ALT greater than 2 times the mean of the ALT concentrations on the first 3 days) in APAP 4 g daily versus APAP 4 g +propylene glycol 5 mL 99% dosing arms. Responders are red, whereas 5 subjects (striped) were the same in both arms.
3.5-16.7 μg/mL), and the mean number of days subjects had a concentration greater than 5 μg/mL was 19 days (range, 6-25 days). The washout period ranged from 15 to 57 days (mean, 21 days).
Propylene Glycol Administration Did Not Affect the Rate of Responders
There was no difference for the primary outcome of percent responders in each crossover treatment group, defined as peak ALT rising to 2 times the baseline ALT. There were 6 of 21 responders (29%) in the APAP only arm compared with 8 of 20 responders (40%) in the APAP + propylene glycol arm (chi-square; P = .59; Figure 3 ).
Specific Subjects Were More Likely to Be Responders in Each Arm
Subjects who were responders in the APAP arm tended to be responders in the APAP + propylene glycol arm; there were 5 subjects who were responders in both arms. Based on calculating all possible permutations, the chance of this occurring at random is 2%. There was no statistically significant difference in age, sex, or ethnicity between these 5 responders and the other subjects ( Figure 3 ).
Addition of propylene glycol Reduced the Percentage of CYP Metabolites Produced
There was a statistically significant reduction of CYP metabolite percentage in the APAP + propylene glycol arm compared with the APAP arm. For all subjects, the mean percentage of CYP metabolites produced was 5.8% in the APAP arm compared with 4.3% for the APAP + propylene glycol arm (P = .018; paired t test). This effect seems to be attributable just to the responders: the mean percentage of CYP metabolites produced in the responders was 7.7% in the APAP arm versus 4.6% in the APAP + propylene glycol arm (P = .050; unpaired t test assuming equal variance). However, there was no significant difference in CYP metabolite percentages for the nonresponders: the percentage of CYP metabolites produced in the APAP arm 5.0% versus the APAP + propylene glycol arm was 4.1% (P = .350; unpaired t test assuming equal variance); see Figure 4 and Table 1 .
Given that the rise of ALT occurred during the second week of dosing, we performed a subset analysis of the CYP metabolite proportions from days 7 to 14. For all subjects, there was no statistically significant difference in CYP metabolite percentages (APAP, 6.3%; vs APAP + propylene glycol, 4.5%; P = .076; paired t test). However, there was a nonsignificant difference in the responders (APAP, 9.8%; vs APAP + propylene glycol, 4.7%; P = .071; unpaired t test assuming equal variance). As seen for all days, there was no effect for the nonresponders (APAP, 5.0%; vs APAP + propylene glycol, 4.3%; P = .583; unpaired t test assuming equal variance).
AST/ALT Concentrations Did Not Differ Between Groups
There was no difference in peak ALT concentrations between arms (APAP, 22.6 U/L; vs APAP + propylene glycol, 21.6 U/L; P = .58). Similarly, there was no difference in peak AST concentrations. The mean ALT concentration was noted to gradually increase on day 6, an effect attributed only to the responders, as the nonresponders had stable ALT concentrations throughout all days. There was also no statistically significant difference in the percent increase of ALT concentrations from day 5 to day 9 or from day 6 to day 9 between the groups; paired nonparametric Wilcoxon test median, 27% versus 15% (P = .91) and median 7% versus 20% (P = .60) for APAP versus APAP-propylene glycol, respectively.
Discussion
APAP poisoning remains a significant clinical problem. 23 There has been little change in the management of toxicity or in the burden of morbidity and mortality. Toxicity is initiated by metabolism of a portion of APAP via the CYP system, primarily CYP2E1. [7] [8] [9] This leads to production of a radical metabolite, NAPQI, and other radical species, leading to a reduction in intracellular glutathione and oxidative stress. 24 The mainstay of treatment remains the administration of N-acetylcysteine, which is thought to replenish glutathione stores, preventing the initiation of a cascade of events leading to hepatocellular injury. 25 There has been suggestion of inhibiting CYP2E1 activity with propylene glycol to make the drug safer or as an alternative mechanism to treat overdoses. 16, 17 Indeed, in our prior study, we hypothesized that the pediatric liquid preparations may be safer because of the presence of excipients that inhibit CYP2E1 and that this may be responsible for the lower rate of toxicity seen among children. In this current study we sought to determine if propylene glycol might have an effect on the subclinical hepatocellular injury seen in humans at a dose that could reasonably be administered, as there is significant evidence in rodents and tissue culture that propylene glycol in high doses prevents toxicity. 9, 17, 18, 26 To this end, we exploited the phenomenon of the subclinical rise seen in ALT following daily therapeutic dosing as a model of human hepatocellular injury. We also wanted to confirm that propylene glycol alone inhibited the production of CYP metabolites in humans, as has been shown in animals, or if this effect in the liquid preparation was attributable to other excipients present in the formulation. 17 We found no difference in the percentage of responders in the APAP + propylene glycol versus APAPonly arms. The failure of propylene glycol to protect against this subclinical hepatocellular injury may be explained by several reasons. First, we could have underdosed propylene glycol and may not have achieved sufficient CYP2E1 inhibition. We limited the amount of propylene glycol based on concerns for toxicity and the amount likely to be tolerated with repeated daily dosing. Indeed, higher doses were administered to animals to obtain adequate inhibition of CYP2E1 to reduce toxicity in overdoses. 17 Second, there was potential for noncompliance with propylene glycol selfdosing, given that the propylene glycol dosing was unsupervised. This is less likely to be an issue, as we observed a similar degree of decrease of CYP-derived metabolites in our prior study, in which subjects were supervised. Third, there may be a mechanism of ALT elevation in the setting of chronic daily dosing that is distinct from the mechanism that leads to acute liver injury in overdose. Fourth, it is possible there may be other CYP-related effects, such us an upregulation of CYP2E1 in daily APAP dosing or a contribution from CYP1A2 and CYP3A, as these have also been implicated in contributing to NAPQI formation. 8, 9 Finally, the protective CYP inhibition in rodents and tissue cultures may not be the case in humans. This is less likely given the clear effect in other species and the demonstrated applicability of rodents as a model for human toxicity.
Our previous crossover APAP dosing study found decreased CYP metabolite production following administration of the liquid formulation, compared with solid formulation, which we theorized was from the presence of propylene glycol in the liquid formulation. 15 In this study, we controlled for other potential confounding substances present in the liquid formulation by administering purified propylene glycol with solid APAP formulation. Our results indicate that propylene glycol specifically inhibits the production of CYP metabolites, given the relative decreased production of CYP metabolites in the APAP + propylene glycol group, similar to our prior study.
Interestingly, we found that the subjects who developed ALT elevation (ie, responders) showed increased CYP inhibition in the presence of propylene glycol compared with the nonresponders. That propylene glycol seemingly inhibited CYP metabolite production but did so in the subjects who developed hepatocellular injury is counterintuitive: if the CYP-derived metabolites were solely causing the rise in ALT, the nonresponders should have exhibited the difference in production of P450-derived metabolites. In addition, we noted that the same subjects were responders in both arms, much more so than would be expect by chance, suggesting there is an inherent difference among the subjects who were responders versus nonresponders.
These results could be explained if the responders had greater baseline CYP2E1 activity compared with nonresponders to the extent that this activity overwhelms the protective effects of propylene glycol. This could be because of induction via environmental factors including alcohol use, diet, nutritional status, exposures to other xenobiotics, polymorphisms of CYP2E1, or other intrinsic factors. CYP2E1 is generally considered a well-conserved metabolizing enzyme. However, recent evidence suggests a pharmacogenomic influence. For example, there is evidence that the CYP2E1*1D polymorphism results in slower APAP oxidative metabolism. 27 Alternatively, susceptibility may be because of a non-CYP-mediated mechanism, such as lower hepatic glutathione stores. In animal models, decreased glutathione stores predispose to the development of hepatocellular injury. 28 However, as we recruited healthy volunteers, we do not suspect that there was a significant hepatic glutathione difference between responders and nonresponders. Last, because we randomly sampled for metabolites, and did not collect 24-hour urine or calculate area under the curve, we could only report proportion of CYP metabolites produced. Therefore, we would not have been able to discern the CYP2E1 inhibition in nonresponders if they had significantly less CYP2E1 activity compared with the responders.
There are several limitations to our study. We were unable to achieve the target number of study subjects, which resulted in underpowering, so we cannot conclude the lack of difference in primary outcome was significant. Had we been able to enroll more subjects, we may have been able to show a statistically significant reduction in the number of responders. However, we would still expect that the same responders would occur in both groups. Consequently, given the results, we do not believe that the effect would have been robust enough to be applied to clinical practice.
Another limitation is that ALT may not be a sufficiently sensitive marker of hepatocellular injury for us to detect difference. Regardless, ALT is a commonly used clinical marker and has been used previously in studies of hepatocellular injury from daily APAP dosing. Also, a mild rise in ALT may not be from the same initiating mechanisms as clinical liver injury following overdose. Although it is logical to assume that ALT rise is because of a mechanism similar to that of hepatocellular injury, we know of scant data to support this. Consequently, our underlying model may be inherently flawed.
Our analysis of the metabolite data is hindered by several limitations. We were unable to collect 24-hour urine or frequent enough serum samples to perform area under the curve calculations. Metabolites were collected at random, not timed, intervals. This is not likely to be significant regarding the ALT measurements similar as we would not expect these to vary over hours. Metabolite levels, however, clearly are affected by timing since dosing. However, we did generate a large number of samples and calculated the percentage of CYP metabolite produced at a given time as a surrogate measure of total metabolite production. Further, the degree of inhibition was similar to that which we observed in our prior study, suggesting consistency in results.
Finally, we were unable to observe subjects with regard to compliance with taking the study medications. Specifically, we did not test serum ethanol or other medication concentrations. There are a number of environmental factors that can affect CYP2E1 activity (such as fasting, diet, alcohol intake, CYP inducers), and as this was an outpatient study, we could not control for all of these. We relied on patient report of taking the study medications reliably, which we believed was adhered to, as there was significant production of measured APAP metabolites.
Conclusions
Propylene glycol reduces the production of CYPderived APAP metabolites; however, at the dose given, we were unable to show that it is protective in a subclinical model of APAP hepatocellular injury. Certain subjects were susceptible to hepatocellular injury, measured as an elevation in ALT concentrations. Subjects who developed hepatocellular injury showed the greatest inhibition of production of CYP-derived metabolites by propylene glycol. This suggests an intrinsic susceptibility to APAP hepatocellular injury that is CYP2E1 mediated but not protected at the degree of CYP2E1 inhibition achieved. This susceptibility requires more investigation and could potentially identify a population that can safely be administered larger APAP doses.
